SCHEMBL1574867

SCHEMBL1574867

COc1cccc(N2CCN(C3CN(C(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)C3)CC2)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.61
HSD17B10 Q99714 3/20 0.61
SMN1; SMN2 Q16637 2/20 0.61
GAA P10253 2/20 0.61
MAPT P10636 3/20 0.58
HTT P42858 2/20 0.54
MAPK1 P28482 2/20 0.54
KDM4E B2RXH2 1/20 0.54
POLB P06746 2/20 0.53
GRIN2B Q13224 1/20 0.52
CA12 O43570 2/20 0.51
CA1 P00915 2/20 0.51
CA2 P00918 2/20 0.51
CA9 Q16790 2/20 0.51
KMT2A Q03164 1/20 0.51
TSHR P16473 2/20 0.50
MAPK10 P53779 1/20 0.50
USP2 O75604 1/20 0.50
TP53 P04637 1/20 0.50
ALOX15 P16050 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1575176 0.90 LMNA (0.51) LMNAHSD17B10SMN1; SMN2GAAMAPT
SCHEMBL1574448 0.90 MAPT (0.66) LMNAHSD17B10SMN1; SMN2GAAMAPT
SCHEMBL1574862 0.87 LMNA (0.57) LMNAHSD17B10SMN1; SMN2GAAMAPT
SCHEMBL1575395 0.85 FAAH (0.60) HTTPOLBGRIN2BKMT2AALDH1A1
SCHEMBL1574330 0.83 MAPT (0.53) LMNAHSD17B10GAAMAPTHTT
SCHEMBL1574888 0.82 LMNA (0.52) LMNAHSD17B10SMN1; SMN2GAAMAPT
SCHEMBL1574765 0.81 LMNA (0.59) LMNAHSD17B10SMN1; SMN2GAAMAPT
SCHEMBL1575625 0.81 LMNA (0.67) LMNAHSD17B10SMN1; SMN2GAAMAPT
SCHEMBL1575324 0.80 PRKAB2 (0.60) LMNAMAPTKMT2AUSP2ALDH1A1
SCHEMBL1576012 0.79 POLB (0.45) LMNAHSD17B10SMN1; SMN2MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2308562-A2 Azetidine ring compounds and drugs comprising the same Ono Pharmaceutical Co., Ltd. (JP) 2011-04-13 EP disclosed
US-7511159-B2 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2009-03-31 US disclosed
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 US disclosed
EP-1698375-A1 AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same EDNRA, LIPG, EDNRB LMNA 1076/4885HSD17B10 1325/4885SMN1; SMN2 1838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.